Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abgenix, Diabetogen to develop antibody for diabetes

Executive Summary

Abgenix and Diabetogen (drugs to treat autoimmune diseases) will collaborate in the development of a fully human monoclonal antibody therapy to treat Type I diabetes and other autoimmune diseases.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register